Market Overview

Why Cytokinetics Is Trading Lower Today

Why Cytokinetics Is Trading Lower Today

Cytokinetics (NASDAQ: CYTK) shares are trading lower on Thursday after the company, Amgen and Servier announced topline results from GALACTIC-HF, a Phase 3 pivotal clinical trial of omecamtiv mecarbil in patients with heart failure with reduced ejection fraction.

The company reported no reduction in the secondary endpoint of CV death was observed.

Cytokinetics is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatment for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The treatment is based on small molecules specifically engineered to increase muscle function and contractility.

Cytokinetics shares traded down 43.10% to $15.74 on Thursday. The stock has a 52-week high of $30.14 and a 52-week low of $7.72.


Related Articles (CYTK)

View Comments and Join the Discussion!

Posted-In: why it's movingNews Health Care Movers Trading Ideas General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at